Liverpool HEP Interactions

Based on drug interaction studies conducted with Epclusa, no clinically significant drug interactions have been observed with the combination of emtricitabine, rilpivirine, and tenofovir DF. Coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (150/150/200/10 mg, once daily) with sofosbuvir/velpatasvir (400/100 mg, once daily) was studied in 24 volunteers. Tenofovir alafenamide Cmax and AUC decreased by 20% and 13%, respectively. Sofosbuvir Cmax and AUC increased by 23% and 37%, respectively. GS-331007 AUC Cmax and Cmin increased by 29%, 48% and 58%, respectively. Velpatasvir Cmax, AUC and Cmin increased by 30%, 50% and 60%, respectively.

Epclusa Prescribing Information, Gilead Science Inc., June 2021.

Coadministration of sofosbuvir/velpatasvir (400/100 mg, once daily) with rilpivirine/emtricitabine/tenofovir-DF (200/25/300 mg, once daily) was studied in 24 healthy volunteers. Sofosbuvir AUC and Cmax increased by 16% and 9%, respectively. GS-331007 AUC and Ctau increased by 4% and 12%, while Cmax decreased by 4%. Velpatasvir AUC and Cmax decreased by 1% and 6%, while Ctau increased by 2%. No dosage adjustments are required.

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Mogalian E, Stamm L M, Osinusi A et al. Clin Infect Dis, 2018; 67(6): 934-940.